Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Apontis Pharma AG's Debt-to-EBITDA or its related term are showing as below:
FRA:APPH's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.65 * Ranked among companies with meaningful Debt-to-EBITDA only.
Apontis Pharma AG (FRA:APPH) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Apontis Pharma AG Debt-to-EBITDA Related Terms
Apontis Pharma AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Apontis Pharma AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:APPH vs ZTS, UTHR, NBIX: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2025) EBITDA data.
Apontis Pharma AG (FRA:APPH) has a Debt-to-EBITDA of 0.00 as of Jun. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Apontis Pharma AG.
Is Apontis Pharma AG's Debt-to-EBITDA too high?
Apontis Pharma AG's current Debt-to-EBITDA is 0.00. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's Debt-to-EBITDA compare to ZTS and UTHR?
Apontis Pharma AG's Debt-to-EBITDA of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Apontis Pharma AG. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apontis Pharma AG's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current Debt-to-EBITDA of 0.00. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current Debt-to-EBITDA is 0.00. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current Debt-to-EBITDA is 0.00 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?
Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued.
The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.
Key valuation signals for FRA:APPH:
Debt-to-EBITDA: 0.00
GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score
Get the complete analysis for FRA:APPH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APPH has been successfully added to your 
